OYSTER POINT PHARMA, INC. (OYST): Price and Financial Metrics


OYSTER POINT PHARMA, INC. (OYST): $4.07

0.21 (+5.44%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OYST to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

OYST POWR Grades


  • Value is the dimension where OYST ranks best; there it ranks ahead of 50.43% of US stocks.
  • The strongest trend for OYST is in Stability, which has been heading down over the past 179 days.
  • OYST's current lowest rank is in the Momentum metric (where it is better than 12.28% of US stocks).

OYST Stock Summary

  • OYST's went public 2.41 years ago, making it older than merely 6.52% of listed US stocks we're tracking.
  • With a price/sales ratio of 13.05, Oyster Point Pharma Inc has a higher such ratio than 88.8% of stocks in our set.
  • With a year-over-year growth in debt of 13,397.52%, Oyster Point Pharma Inc's debt growth rate surpasses 99.72% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Oyster Point Pharma Inc, a group of peers worth examining would be OSIS, QUOT, REKR, ISR, and BYND.
  • OYST's SEC filings can be seen here. And to visit Oyster Point Pharma Inc's official web site, go to www.oysterpointrx.com.

OYST Valuation Summary

  • 500 - Internal server error
  • OYST's EV/EBIT ratio has moved up 9.7 over the prior 22 months.
  • Over the past 22 months, OYST's price/sales ratio has gone up 5.35.

Below are key valuation metrics over time for OYST.

Stock Date P/S P/B P/E EV/EBIT
OYST 2021-08-31 NA 2.3 -4.3 -2.4
OYST 2021-08-30 NA 2.3 -4.4 -2.4
OYST 2021-08-27 NA 2.4 -4.5 -2.6
OYST 2021-08-26 NA 2.4 -4.5 -2.6
OYST 2021-08-25 NA 2.3 -4.5 -2.5
OYST 2021-08-24 NA 2.3 -4.3 -2.4

OYST's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OYST has a Quality Grade of D, ranking ahead of 7.23% of graded US stocks.
  • OYST's asset turnover comes in at 0 -- ranking 440th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows OYST's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA 18.015
2021-03-31 0 NA 14.414
2020-12-31 0 NA 13.189
2020-09-30 0 NA 16.062
2020-06-30 0 NA 34.495

OYST Price Target

For more insight on analysts targets of OYST, see our OYST price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $55.50 Average Broker Recommendation 1.5 (Moderate Buy)

OYST Stock Price Chart Interactive Chart >

Price chart for OYST

OYST Price/Volume Stats

Current price $4.07 52-week high $21.01
Prev. close $3.86 52-week low $3.53
Day low $3.67 Volume 74,000
Day high $4.13 Avg. volume 172,671
50-day MA $7.65 Dividend yield N/A
200-day MA $11.33 Market Cap 108.54M

OYSTER POINT PHARMA, INC. (OYST) Company Bio


Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its lead product candidate, OC-01, is a nicotinic acetylcholine receptor agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. The company was founded by Michael and is Ackermann in June 30, 2015 headquartered in Princeton, NJ.


OYST Latest News Stream


Event/Time News Detail
Loading, please wait...

OYST Latest Social Stream


Loading social stream, please wait...

View Full OYST Social Stream

Latest OYST News From Around the Web

Below are the latest news stories about Oyster Point Pharma Inc that investors may wish to consider to help them evaluate OYST as an investment opportunity.

Oyster Point Pharma, Inc. (OYST) Q4 2021 Earnings Call Transcript

This evening, we issued a press release containing our fourth quarter and full year ended December 31, 2021, financial results and recent business highlights. In addition, our earnings press release and our Form 10-K, which were filed with the SEC after the close of market today, are available on our website under the investors and news section at www.oysterpointrx.com.

Yahoo | February 25, 2022

Oyster Point Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

FDA Approved TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease on October 15, 2021TYRVAYA Nasal Spray Net Product Revenue of $1.2 Million in Q4’21, plus $5.4 Million Recognized from Ji Xing Pharmaceuticals (Ji Xing) License Agreement in Q4’21Over 5,500 TYRVAYA Prescriptions Filled; Prescriptions Written by Approximately 1,900 Unique Eye Care Professionals in November and December 2021$50 Million Drawn on Second Tranche from OrbiMed Royalty

Yahoo | February 24, 2022

Oyster Point Pharma Announces TYRVAYA™ Nasal Spray Now Covered by Express Scripts

One of the largest pharmacy benefit management (PBM) companies in the United States has added TYRVAYA (varenicline solution) Nasal Spray to National Preferred, Basic and High-Performance Formularies, effective February 19, 2022. FDA Approved TYRVAYA Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease on October 15, 2021. TYRVAYA Nasal Spray became commercially available at U.S. pharmacies and for home delivery in November 2021. PRINCETON, N.J., Feb. 22, 2022 (GLOBE NEWSWIR

Yahoo | February 22, 2022

Oyster Point Pharma To Report Fourth Quarter And Full Year 2021 Financial Results On February 24, 2022

Conference Call and Webcast Scheduled for February 24, 2022, 4:30 p.m. ETPRINCETON, N.J., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that it will report fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, after the market close. The announce

Yahoo | February 16, 2022

Mass General Brigham, Inc Buys DocuSign Inc, Oyster Point Pharma Inc, Dada Nexus, Sells iShares ...

Investment company Mass General Brigham, Inc (Current Portfolio) buys DocuSign Inc, Oyster Point Pharma Inc, Dada Nexus, Airbnb Inc, sells iShares Core S&P 500 ETF, iShares Core U.S.

Yahoo | January 20, 2022

Read More 'OYST' Stories Here

OYST Price Returns

1-mo -38.70%
3-mo -62.83%
6-mo -60.52%
1-year -77.29%
3-year N/A
5-year N/A
YTD -77.71%
2021 -2.98%
2020 -23.00%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8528 seconds.